About Us
Pioneering Precision Viral Immunotherapy for Patients Fighting Solid Tumors
Who We Are
The cancer treatment paradigm has shifted dramatically, providing evidence that the immune system can be educated to recognize and eliminate the patient’s tumor cells. The mechanism of action of viral immunotherapies is unique in combining both an anti-tumor component and an immune-stimulatory component. Together, this leads to an “in-situ immunization” effect against the injected tumor and uninjected metastases.
At Candel Therapeutics, we are developing viral immunotherapies that are designed to cause in-situ immunization against the unique antigens and neoantigens presented when tumor cells lyse and stimulate activation of both innate and adaptive immune mechanisms. The patient and tumor-specific memory response has been shown to produce a systemic and sustained anti-cancer effect based on a highly individualized T cell response against the injected tumor and uninjected metastases and has the potential to change disease outcomes across a variety of indications.
Candel’s investigational viral immunotherapies are designed to deliver durable clinical benefit, from preventing recurrence in curative-intent settings to extending survival in advanced disease, while maintaining quality of life.
At Candel Therapeutics, we are developing viral immunotherapies that are designed to cause in-situ immunization against the unique antigens and neoantigens presented when tumor cells lyse and stimulate activation of both innate and adaptive immune mechanisms. The patient and tumor-specific memory response has been shown to produce a systemic and sustained anti-cancer effect based on a highly individualized T cell response against the injected tumor and uninjected metastases and has the potential to change disease outcomes across a variety of indications.
Candel’s investigational viral immunotherapies are designed to deliver durable clinical benefit, from preventing recurrence in curative-intent settings to extending survival in advanced disease, while maintaining quality of life.
How We Innovate
We harness the power of our proprietary virus-based approaches and elicit a broad, potent immune response against solid tumors and their metastases.
OUR COMMITMENT TO PATIENT CARE
Our mission is to save, extend, and improve the lives of patients through viral immunotherapies.
